| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:BACE1-IN-13
CAS:1397683-26-9
Package:50mg;5mg
|
2-Pyrazinecarboxamide, N-[3-[(6R)-4-amino-2-cyano-6,7-dihydro-6-methylpyrazolo[1,5-a]pyrazin-6-yl]-4-fluorophenyl]-5-methoxy- manufacturers
- BACE1-IN-13
-
- $0.00 / 50mg
-
2025-10-27
- CAS:1397683-26-9
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 2-Pyrazinecarboxamide, N-[3-[(6R)-4-amino-2-cyano-6,7-dihydro-6-methylpyrazolo[1,5-a]pyrazin-6-yl]-4-fluorophenyl]-5-methoxy- Basic information |
| | 2-Pyrazinecarboxamide, N-[3-[(6R)-4-amino-2-cyano-6,7-dihydro-6-methylpyrazolo[1,5-a]pyrazin-6-yl]-4-fluorophenyl]-5-methoxy- Chemical Properties |
| density | 1.50±0.1 g/cm3(Predicted) | | pka | 8.91±0.70(Predicted) |
| | 2-Pyrazinecarboxamide, N-[3-[(6R)-4-amino-2-cyano-6,7-dihydro-6-methylpyrazolo[1,5-a]pyrazin-6-yl]-4-fluorophenyl]-5-methoxy- Usage And Synthesis |
| Uses | BACE1-IN-13 (Compound 36) is an orally active BACE1 inhibitor with an IC50 value of 2.9 nM. BACE1-IN-13 is highly potent in hAβ42 cell (IC50 = 1.3 nM). BACE1-IN-13 has cardiovascularly safty and elicits sustained Aβ42 reduction in mouse and dog animal models[1]. | | References | [1] Peschiulli A, et al. A Brain-Penetrant and Bioavailable Pyrazolopiperazine BACE1 Inhibitor Elicits Sustained Reduction of Amyloid β In Vivo. ACS Med Chem Lett. 2021 Dec 1;13(1):76-83. DOI:10.1021/acsmedchemlett.1c00445 |
| | 2-Pyrazinecarboxamide, N-[3-[(6R)-4-amino-2-cyano-6,7-dihydro-6-methylpyrazolo[1,5-a]pyrazin-6-yl]-4-fluorophenyl]-5-methoxy- Preparation Products And Raw materials |
|